Literature DB >> 9078354

A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery.

K M Sullivan1, J Storek, K J Kopecky, J Jocom, G Longton, M Flowers, M Siadak, J Nims, R P Witherspoon, C Anasetti, F R Appelbaum, R A Bowden, C D Buckner, S W Crawford, H J Deeg, J A Hansen, G B McDonald, J E Sanders, R Storb.   

Abstract

To determine whether intravenous immunoglobulin (IVIg) given monthly from day 90 to day 360 posttransplantation decreased the incidence of late infection, chronic graft-vs.-host disease (GVHD), and obliterative bronchiolitis after marrow transplantation, patients were assigned randomly to receive either IVIg (500 mg/kg/month) or no IVIg prophylaxis. Participants were registered before transplantation, and 250 patients (123 IVIg and 127 control) were evaluable for events after day 100. The two groups were balanced for age, marrow source, cytomegalovirus (CMV) seropositivity, pretransplantation conditioning, and prophylaxis for infection and GVHD. Between days 100 and 365 posttransplantation, the incidence of bacteremia or septicemia per 100 patient-days of risk was 0.10 in the IVIg group and 0.12 in the controls (p = not significant). During the same period, the incidence of localized infection was marginally higher in control patients than in IVIg recipients (0.44 vs. 0.24, respectively; relative risk [RR] 1.46, p < 0.07). Administration of IVIg prophylaxis had no effect on survival, the incidence of obliterative bronchiolitis, severity of airflow obstruction, or the incidence or mortality of chronic GVHD. After discontinuing IVIg prophylaxis at day 360, subsequent recovery of endogeneous humoral immunity was impaired (serum IgG1 and IgA levels were significantly lower than controls at day 730), and total infections were less common in the second year in control patients than in former IVIg recipients (0.12 vs 0.19, respectively; RR 0.61, p = 0.03). We conclude that in the absence of hypogammaglobulinemia, monthly administration of IVIg given from day 90 to 360 does not reduce late complications and may impair long-term humoral immune recovery after marrow transplantation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9078354

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  13 in total

Review 1.  Post-transplant immune recovery and the implication for infection risk.

Authors:  Michael E Trigg
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 2.  Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.

Authors:  Vir-Singh Negi; Sriramulu Elluru; Sophie Sibéril; Stéphanie Graff-Dubois; Luc Mouthon; Michel D Kazatchkine; Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2007-03-11       Impact factor: 8.317

3.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

4.  9 Human Immunoglobulins.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

Review 5.  Long-Term Survivorship after Hematopoietic Cell Transplantation: Roadmap for Research and Care.

Authors:  Minoo Battiwalla; André Tichelli; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2016-11-03       Impact factor: 5.742

6.  Anti-inflammatory IgG production requires functional P1 promoter in β-galactoside α2,6-sialyltransferase 1 (ST6Gal-1) gene.

Authors:  Mark B Jones; Mehrab Nasirikenari; Amit A Lugade; Yasmin Thanavala; Joseph T Y Lau
Journal:  J Biol Chem       Date:  2012-03-15       Impact factor: 5.157

Review 7.  Have we made progress in the management of chronic graft-vs-host disease?

Authors:  Stephanie J Lee
Journal:  Best Pract Res Clin Haematol       Date:  2010-11-02       Impact factor: 3.020

8.  B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation.

Authors:  Alexandra M Miggelbrink; Brent R Logan; Rebecca H Buckley; Roberta E Parrott; Christopher C Dvorak; Neena Kapoor; Hisham Abdel-Azim; Susan E Prockop; David Shyr; Hélène Decaluwe; Imelda C Hanson; Alfred Gillio; Blachy J Dávila Saldaña; Hermann Eibel; Gregory Hopkins; Jolan E Walter; Jennifer S Whangbo; Donald B Kohn; Jennifer M Puck; Morton J Cowan; Linda M Griffith; Elie Haddad; Richard J O'Reilly; Luigi D Notarangelo; Sung-Yun Pai
Journal:  Blood       Date:  2018-05-04       Impact factor: 22.113

Review 9.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Authors:  Juan Gea-Banacloche; Krishna V Komanduri; Paul Carpenter; Sophie Paczesny; Stefanie Sarantopoulos; Jo-Anne Young; Nahed El Kassar; Robert Q Le; Kirk R Schultz; Linda M Griffith; Bipin N Savani; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-14       Impact factor: 5.742

Review 10.  Reconstitution of the immune system after hematopoietic stem cell transplantation in humans.

Authors:  Jan Storek; Michelle Geddes; Faisal Khan; Bertrand Huard; Claudine Helg; Yves Chalandon; Jakob Passweg; Eddy Roosnek
Journal:  Semin Immunopathol       Date:  2008-10-24       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.